Vanguard Group Inc Acurx Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 145,537 shares of ACXP stock, worth $606,889. This represents 0.0% of its overall portfolio holdings.
Number of Shares
145,537
Previous 529,349
72.51%
Holding current value
$606,889
Previous $206,000
64.08%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ACXP
# of Institutions
37Shares Held
2.71MCall Options Held
62.9KPut Options Held
56.9K-
Armistice Capital, LLC New York, NY1.08MShares$4.5 Million0.01% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$1.53 Million0.08% of portfolio
-
Geode Capital Management, LLC Boston, MA146KShares$610,5040.0% of portfolio
-
Morgan Stanley New York, NY106KShares$442,8580.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny87.8KShares$366,0460.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $48.2M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...